What one share of Vera Therapeutics holds
We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Vera Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$5.90 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.97 |
| Cash and investments | $6.93 |
| Debt | $1.04 |
| Book value | $5.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$166.93 | $0.31 | −$109.10 | — | −$279.24 |
| 2021 | — | −$2.43 | — | — | — | $5.18 |
| 2022 | — | −$3.35 | $0.00 | −$2.55 | — | $2.89 |
| 2023 | — | −$2.25 | $0.00 | −$2.16 | — | $2.38 |
| 2024 | — | −$2.75 | $0.02 | −$2.45 | — | $10.43 |
| 2025 | — | −$4.66 | $0.01 | −$3.76 | — | $9.41 |
Common questions about Vera Therapeutics
How much does one share of Vera Therapeutics earn?
Over the last 12 months, Vera Therapeutics lost $5.90 for each share.
Does Vera Therapeutics pay a dividend?
Vera Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Vera Therapeutics’s book value per share?
Vera Therapeutics’s book value is $5.66 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Vera Therapeutics have?
Each share of Vera Therapeutics has $6.93 of cash and investments and $1.04 of debt, as of June 30, 2026.
What is Vera Therapeutics’s free cash flow per share?
−$4.97 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Vera Therapeutics bought back shares?
Vera Therapeutics’s share count rose about 19975% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.